GenNext Technologies and Agilent formed a collaboration that promises to transform structural biology research for biopharmaceutical companies. The integration of GenNext’s AutoFox Protein Footprinting System with Agilent’s 6560 Ion Mobility Quadrupole Time-of-Flight (IM-QTOF) LC/MS System presents an unparalleled approach to detailed protein structure analysis and biomolecular interaction studies. This fusion of technology platforms enables biopharmaceutical researchers to achieve deeper insights with greater ease, facilitating high-value decisions faster than ever before.

The two companies are combining the latest in HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics. The state-of-the art structural biology workflow starts with the GenNext Flash Oxidation (Fox®) Protein Footprinting System performing covalent labeling of biotherapeutic products. Then, the ZenoTOF 7600 system from SCIEX is employed for mass spectrometry analysis. Finally, GenNext’s FoxWare^® Data Processing Software is leveraged to execute high resolution HOS data analysis.

Together, GenNext and Emery Pharma deliver best-in-class pharmaceutical functional and structural analysis for allosteric and monoclonal antibody therapeutics. For clients seeking contract research, the GenNext/Emery Pharma team will generate data-rich insights to help them accelerate the approval of biotherapeutics and to develop safer, more effective, and less expensive therapeutic products.